As Congress returns to work after a brief recess, lawmakers remain focused on prescription drug prices.
The Senate Committee on Finance will hold a Feb. 26 hearing on the high cost of drug prices, with testimony from leaders of seven pharmaceutical companies. Executives from AbbVie, AstraZeneca, Bristol-Myers Squib, Johnson & Johnson, Merck, Pfizer, and Sanofi well appear before the committee and explain their pricing practices.
This will be the second of a three-part hearing series to examine increases in prescription drug prices.
Meanwhile, lawmakers on the Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies will further examine the opioid addiction epidemic during a Feb. 28 hearing on prevention, treatment, and recovery options at the state and local levels.
Infectious Disease Prevention and Response
The House Energy and Commerce Subcommittee on Oversight and Investigations will hold a Feb. 27 hearing reviewing responses to the growing public health threat of measles outbreaks.
The Senate Committee on Health, Education, Labor, and Pensions also will examine this concern in a March 5 hearing on vaccinations to prevent disease outbreaks.
